Neurology Letters

Keyword Index

A

  • Acute Brainstem syndrome Acute Brainstem syndrome with NMOSD and related to systemic lupus erythematosus, A Rare Case Report (PP-02) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Acute disseminated encephalomyelitis Acute disseminated encephalomyelitis (ADEM), Report A Rare Case of Refractory form to treatment (PP-03) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Acute disseminated encephalomyelitis Acute disseminated encephalomyelitis following vaccination against SARS-cov-2: a case report (PP-04) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Acute Optic Neuritis Optic neuritis updates (ORP-57) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Adverse effect Comparison of COVID-19 infection, Acute Relapse, and Adverse Effects Following COVID-19 Vaccination Between Patients with Multiple Sclerosis and Other Neurological Disorders (PP-29) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Alopecia areata Alopecia universalis in a patient under treatment of Ocrelizumab after switching from Rituximab (PP-06) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Alzheimer's disease Review Current and Emerging Treatment Options for Alzheimer's Disease [Volume 2, Issue 1, 2023, Pages 1-5]
  • Alzheimer’s disease Regional cerebral blood flow and brain atrophy in mild cognitive impairment and Alzheimer's disease [Volume 2, Issue 1, 2023, Pages 16-24]
  • Amyotrophic Lateral Sclerosis Current understanding of the association between Amyotrophic lateral sclerosis and frontotemporal dementia: Letter to Editor [Volume 2, Issue 1, 2023, Pages 42-43]
  • Anti-epileptic drug resistance Quantitative Electroencephalography Findings in Treatment-resistant and Responsive Patients with Idiopathic Generalized Tonic-Clonic Epilepsy [Volume 2, Issue 1, 2023, Pages 6-12]
  • Anti-TNF-α Demyelinating Disease Following Anti-TNFa Treatment (Adalimumab) in Patients with psoriasis: A Case Report (PP-13) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Artificial intelligence The role of Artificial Intelligence in cognitive impairment assessment by MRI in people with MS (Iranian Research) (ORP-09) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Artificial intelligence The Role of Advanced MRI Techniques and Artificial Intelligence-based Methods In Diagnosis of Multiple Sclerosis (ORP-42) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Artificial intelligence Artificial intelligence in multiple sclerosis imaging: advancements, benefits, and challenges (PP-07) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Attack Definition and treatment of the multiple sclerosis relapse (ORP-10) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Atypical imaging Case presentation, Atypical imaging of MS (PP-11) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Auditory Function The Effect of Multiple Sclerosis on Peripheral Audio-Vestibular System (PP-17) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Autoimmune Disease Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy diagnosis and management: A case report study (ORP-28) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Autoimmune encephalitis Diagnostic approach to autoimmune encephalitis (ORP-15) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Autoimmune encephalitis Treatment approach in Autoimmune encephalitis (ORP-36) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Autonomic dysfunction Autonomic dysfunction and fatigue in Parkinson’s disease: a report from Kenya [Volume 2, Issue 1, 2023, Pages 47-50]
  • AVN Femoral head AVN concept and treatments (ORP-16) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

B

  • Baló’s concentric sclerosis MS Variants (ORP-38) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Bariatric surgery Comparing the Impact of Bariatric Surgery and Diet Therapy on MS Disease-Related Symptoms: A Systematic Review Study (PP-12) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Basal ganglia calcification Diagnosis of multiple sclerosis and Fahr's Disease in a young woman: A case report (PP-15) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Benign Paroxysmal Positional Vertigo Benign Paroxysmal Positioning Vertigo in Multiple Sclerosis (PP-09) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Biomarkers Exploring the Potential of Biomarkers for Early Diagnosis and Management of Sporadic Creutzfeldt - Jakob disease; A Review [Volume 2, Issue 2, 2023, Pages 78-86]
  • Biomarkers MS Prodrome; Is it a fact? (ORP-02) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Brain stimulation Brain Stimulation for Cognitive impairment in Multiple Sclerosis (ORP-17) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Breastfeeding Multiple sclerosis, Pregnancy, Breastfeeding (ORP-40) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

C

  • Cardiovascular autonomic dysfunction Cardiovascular autonomic dysfunction in MS (PP-10) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Central nervous system The Interplay Between the Gut Microbiome and Neurological Disorders: Exploring the Gut-Brain Axis [Volume 2, Issue 1, 2023, Pages 25-29]
  • Cervical MRI Spinal cord MRI in multiple sclerosis; diagnostic, prognostic, and clinical value (ORP-55) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Clinical trial A narrative review on the dietary interventions in multiple sclerosis (ORP-03) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Clinical trial Effect of dynamic neuromuscular stabilization on fatigue and spasticity in people with multiple sclerosis: a randomized controlled trial (ORP-37) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Cognitive dysfunction Relationship between severity of symptoms of sleep disorders and information processing speed in people with multiple sclerosis (ORP-53) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Cognitive Functions Cognitive Functions of Patients with Post Stroke Depression: Comparative Study on Executive Functions, Processing Speed, and Episodic Memory [Volume 2, Issue 2, 2023, Pages 87-96]
  • Cognitive Impairment The role of Artificial Intelligence in cognitive impairment assessment by MRI in people with MS (Iranian Research) (ORP-09) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • COVID-19 COVID-19 vaccine-hesitancy is associated with lower cortical volume in elderly individuals [Volume 2, Issue 1, 2023, Pages 35-41]
  • COVID-19 Acute Relapses of Neuromyelitis Optica Spectrum Disorder After COVID-19 Vaccination Shot, Among Iranian Patients (PP-05) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • COVID-19 Comparison of COVID-19 infection, Acute Relapse, and Adverse Effects Following COVID-19 Vaccination Between Patients with Multiple Sclerosis and Other Neurological Disorders (PP-29) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • COVID-19 vaccination Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review (PP-25) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Creutzfeldt-Jakob disease Exploring the Potential of Biomarkers for Early Diagnosis and Management of Sporadic Creutzfeldt - Jakob disease; A Review [Volume 2, Issue 2, 2023, Pages 78-86]
  • Criteria Neuromyelitis Optica Spectrum Disorders (NMOSD); Diagnostic criteria (ORP-56) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Crocin The effects of crocin on inflammatory biomarkers and mental health in patients with multiple sclerosis: a randomized, double-blinded clinical trial (ORP-63) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • CSF Diagnostic approach to autoimmune encephalitis (ORP-15) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

D

  • Deep Learning Artificial intelligence in multiple sclerosis imaging: advancements, benefits, and challenges (PP-07) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Demyelinated plaques Diagnosis of multiple sclerosis and Fahr's Disease in a young woman: A case report (PP-15) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Demyelinating Disease Demyelinating Disease Following Anti-TNFa Treatment (Adalimumab) in Patients with psoriasis: A Case Report (PP-13) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Diagnosis Review of McDonald criteria (ORP-20) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Diagnosis Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria (ORP-22) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Diagnosis Neuromyelitis Optica Spectrum Disorders (NMOSD); Diagnostic criteria (ORP-56) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Diet A narrative review on the dietary interventions in multiple sclerosis (ORP-03) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Diet Nutritional recommendations in multiple sclerosis patients: a narrative review (ORP-46) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Dimethyl fumarate Patients monitoring during treatment with Dimethyl fumarate (ORP-23) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Diplopia Ophthalmology in multiple sclerosis (ORP-47) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Disability Optical Coherence Tomography (OCT) Measurements and Disability in Multiple Sclerosis (MS): Protocol of Systematic Review [Volume 2, Issue 1, 2023, Pages 44-46]
  • Disability Clinical Outcome and Volumetric MRI Assessment of Brain and Cervical Spinal Cord Area in Secondary Progressive Multiple Sclerosis Patients Treated with Rituximab: one-year follow-up (ORP-08) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Disease-Modifying Therapies Patients monitoring during treatment with Teriflunomide (ORP-41) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Dix-Hallpike Maneuver Benign Paroxysmal Positioning Vertigo in Multiple Sclerosis (PP-09) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Dizziness The Effect of Multiple Sclerosis on Peripheral Audio-Vestibular System (PP-17) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • DMD Patients Monitoring During Treatment With Injectable DMDs (INF and GA) (ORP-11) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • DMT MS and cognition: review of clinical, neuro-radiological features, and treatment (ORP-18) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • DMT Treatment escalation vs early high efficacy treatment in multiple sclerosis (cons and pros) (ORP-45) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

E

  • EDSS Physical disability assessment: EDSS calculation (ORP-05) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • EEG Pattern EEG Patterns in MS-related epilepsy A literature Review (ORP-26) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Electroencephalogram EEG Patterns in MS-related epilepsy A literature Review (ORP-26) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Encephalitis Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy diagnosis and management: A case report study (ORP-28) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Encephalopathy A middle-aged woman with history of Multiple sclerosis presented with sub-acute encephalopathy (ORP-58) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Environmental Factors MS and Environmental Factors (ORP-61) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Epilepsy Defining seizure type and frequency, and analyzing MRI and EEG findings in MS populations of Khorasan. A cross-sectional study (ORP-21) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Epilepsy EEG Patterns in MS-related epilepsy A literature Review (ORP-26) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Episodic memory Cognitive Functions of Patients with Post Stroke Depression: Comparative Study on Executive Functions, Processing Speed, and Episodic Memory [Volume 2, Issue 2, 2023, Pages 87-96]
  • Episodic memory Long-term and Short-term Episodic Memory Dysfunction in Female MS Patients (PP-18) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Escalation Escalation or high-efficacy disease-modifying therapies in multiple sclerosis [Volume 2, Issue 2, 2023, Pages 106-108]
  • Essential Tremor Comparison of the Effect of Botulinum Toxin Injection Under Ultrasound Guidance and Oral Propranolol in the Treatment of Moderate to Severe Essential Hand Tremor [Volume 2, Issue 2, 2023, Pages 69-77]
  • Exacerbation Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review (PP-25) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Executive Functions Cognitive Functions of Patients with Post Stroke Depression: Comparative Study on Executive Functions, Processing Speed, and Episodic Memory [Volume 2, Issue 2, 2023, Pages 87-96]
  • Exercise MS and exercise (PP-23) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

F

  • Fahr's Disease Diagnosis of multiple sclerosis and Fahr's Disease in a young woman: A case report (PP-15) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Frontotemporal Dementia Current understanding of the association between Amyotrophic lateral sclerosis and frontotemporal dementia: Letter to Editor [Volume 2, Issue 1, 2023, Pages 42-43]
  • Future of MS Horizons of MS therapy: during 30 years (ORP-06) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

G

  • Gastrointestinal Multiple sclerosis, infectious and Gastrointestinal complications (ORP-39) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • GFAP astrocytopathy Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy diagnosis and management: A case report study (ORP-28) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Guillain–Barré Syndrome Guillain-Barré syndrome in remission of Ulcerative colitis: a case report [Volume 2, Issue 1, 2023, Pages 13-15]
  • Gut-brain axis The Interplay Between the Gut Microbiome and Neurological Disorders: Exploring the Gut-Brain Axis [Volume 2, Issue 1, 2023, Pages 25-29]
  • Gut-brain axis Gut-Brain axis and MS: Is this true? (ORP-29) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Gut microbiota The Interplay Between the Gut Microbiome and Neurological Disorders: Exploring the Gut-Brain Axis [Volume 2, Issue 1, 2023, Pages 25-29]

H

  • Hearing loss The Effect of Multiple Sclerosis on Peripheral Audio-Vestibular System (PP-17) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Helicobacter pylori Can helicobacter pylori infection reduce the risk of Multiple sclerosis? A systematic review and meta-analysis [Volume 2, Issue 2, 2023, Pages 97-105]
  • Hesitancy COVID-19 vaccine-hesitancy is associated with lower cortical volume in elderly individuals [Volume 2, Issue 1, 2023, Pages 35-41]
  • HTN Headache first manifestation of Multiple Sclerosis (PP-19) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

I

  • Idiopathic generalized epilepsy Quantitative Electroencephalography Findings in Treatment-resistant and Responsive Patients with Idiopathic Generalized Tonic-Clonic Epilepsy [Volume 2, Issue 1, 2023, Pages 6-12]
  • Imaging Artificial intelligence in multiple sclerosis imaging: advancements, benefits, and challenges (PP-07) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Immune signaling The Interplay Between the Gut Microbiome and Neurological Disorders: Exploring the Gut-Brain Axis [Volume 2, Issue 1, 2023, Pages 25-29]
  • Immunopathophysiology Update on inflammation, neurodegeneration and immunoregulation in MS (ORP-44) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Impulse-Control Disorders Restless Leg Syndrome and Impulse-Control Disorders in Parkinson’s Disease: Observational study [Volume 2, Issue 1, 2023, Pages 51-54]
  • Infection Can helicobacter pylori infection reduce the risk of Multiple sclerosis? A systematic review and meta-analysis [Volume 2, Issue 2, 2023, Pages 97-105]
  • Inflammatory bowel disease Guillain-Barré syndrome in remission of Ulcerative colitis: a case report [Volume 2, Issue 1, 2023, Pages 13-15]
  • Intolerance of Punishment Multiple Sclerosis (MS) and Legal Medical Doctrines (ORP-60) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Iran Sleep Disturbances and Disease Characteristics of Patients with Multiple Sclerosis in Iran: A Cross-sectional Study (ORP-32) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

L

  • Legal medicine Multiple sclerosis and legal medicine (ORP-34) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Legal medicine Multiple Sclerosis (MS) and Legal Medical Doctrines (ORP-60) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Lesions The role of stereotactic biopsy in atypical brain lesions (ORP-52) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Limitations Artificial intelligence in multiple sclerosis imaging: advancements, benefits, and challenges (PP-07) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Lingual dystonia Lingual dystonia as the first manifestation of multiple sclerosis (PP-22) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Lupus Acute Brainstem syndrome with NMOSD and related to systemic lupus erythematosus, A Rare Case Report (PP-02) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

M

  • Machine Learning The role of Artificial Intelligence in cognitive impairment assessment by MRI in people with MS (Iranian Research) (ORP-09) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Magnetic resonance imaging Clinical Outcome and Volumetric MRI Assessment of Brain and Cervical Spinal Cord Area in Secondary Progressive Multiple Sclerosis Patients Treated with Rituximab: one-year follow-up (ORP-08) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Magnetic resonance imaging The role of Artificial Intelligence in cognitive impairment assessment by MRI in people with MS (Iranian Research) (ORP-09) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Management Treatment approach in Autoimmune encephalitis (ORP-36) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Management Management of seizure in patients with multiple sclerosis (ORP-51) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Marburg variant of multiple sclerosis MS Variants (ORP-38) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Medical Malpractice Multiple Sclerosis (MS) and Legal Medical Doctrines (ORP-60) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Memory Mind and Art (ORP-01) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Meta-analysis Can helicobacter pylori infection reduce the risk of Multiple sclerosis? A systematic review and meta-analysis [Volume 2, Issue 2, 2023, Pages 97-105]
  • Methylprednisolone Definition and treatment of the multiple sclerosis relapse (ORP-10) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Microbiota Current Updates on the Use of Probiotics as a New Treatment Option for Multiple Sclerosis (ORP-50) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Modifiable MS and Environmental Factors (ORP-61) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MOGAD Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria (ORP-22) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MRI Typical MRI lesions of multiple sclerosis in the brain and spinal cord (ORP-13) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MRI Advanced imaging for multiple sclerosis (ORP-14) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MRI Diagnostic approach to autoimmune encephalitis (ORP-15) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MRI Spinal cord MRI in multiple sclerosis; diagnostic, prognostic, and clinical value (ORP-55) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MS The importance of vestibular evaluation and rehabilitation in improving the balance in MS patients (ORP-04) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MS Patient monitoring during treatment with natalizumab (ORP-24) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MS Ophthalmology in multiple sclerosis (ORP-47) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MS Case presentation, Atypical imaging of MS (PP-11) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MS Headache first manifestation of Multiple Sclerosis (PP-19) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MSFC How to estimate the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis? (ORP-43) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MS Prodrome Criteria MS Prodrome; Is it a fact? (ORP-02) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • MS therapeutics targets disease course Horizons of MS therapy: during 30 years (ORP-06) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Personalized Treatment for Multiple Sclerosis: The Role of Precision Medicine [Volume 2, Issue 1, 2023, Pages 30-34]
  • Multiple Sclerosis Optical Coherence Tomography (OCT) Measurements and Disability in Multiple Sclerosis (MS): Protocol of Systematic Review [Volume 2, Issue 1, 2023, Pages 44-46]
  • Multiple Sclerosis Can helicobacter pylori infection reduce the risk of Multiple sclerosis? A systematic review and meta-analysis [Volume 2, Issue 2, 2023, Pages 97-105]
  • Multiple Sclerosis Escalation or high-efficacy disease-modifying therapies in multiple sclerosis [Volume 2, Issue 2, 2023, Pages 106-108]
  • Multiple Sclerosis Mind and Art (ORP-01) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis A narrative review on the dietary interventions in multiple sclerosis (ORP-03) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Physical disability assessment: EDSS calculation (ORP-05) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Horizons of MS therapy: during 30 years (ORP-06) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Women and Multiple Sclerosis (ORP-07) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis The role of Artificial Intelligence in cognitive impairment assessment by MRI in people with MS (Iranian Research) (ORP-09) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Definition and treatment of the multiple sclerosis relapse (ORP-10) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Patients Monitoring During Treatment With Injectable DMDs (INF and GA) (ORP-11) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Everything we need to know about vaccination in MS (ORP-12) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Typical MRI lesions of multiple sclerosis in the brain and spinal cord (ORP-13) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Advanced imaging for multiple sclerosis (ORP-14) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Brain Stimulation for Cognitive impairment in Multiple Sclerosis (ORP-17) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis MS and cognition: review of clinical, neuro-radiological features, and treatment (ORP-18) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Comorbidity in patients with MS (ORP-19) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Review of McDonald criteria (ORP-20) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Defining seizure type and frequency, and analyzing MRI and EEG findings in MS populations of Khorasan. A cross-sectional study (ORP-21) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Patients monitoring during treatment with Dimethyl fumarate (ORP-23) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis New Technological Approach to Physical Therapy in Patients with Multiple Sclerosis (ORP-25) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis EEG Patterns in MS-related epilepsy A literature Review (ORP-26) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Epidemiological view of national MS registry in Iran (NMSRI) (ORP-27) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Gut-Brain axis and MS: Is this true? (ORP-29) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Multiple sclerosis and viral hepatitis (ORP-30) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Lower urinary tract dysfunction in Multiple Sclerosis, Updates (ORP-31) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Sleep Disturbances and Disease Characteristics of Patients with Multiple Sclerosis in Iran: A Cross-sectional Study (ORP-32) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Effect of eight weeks of respiratory muscle training on respiratory capacity, functional capacity, and quality of life on subjects with mild to moderate relapsing-remitting multiple sclerosis (ORP-33) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Multiple sclerosis and legal medicine (ORP-34) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Optic neuritis and autoimmune optic neuropathies (ORP-35) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Effect of dynamic neuromuscular stabilization on fatigue and spasticity in people with multiple sclerosis: a randomized controlled trial (ORP-37) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Multiple sclerosis, infectious and Gastrointestinal complications (ORP-39) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Multiple sclerosis, Pregnancy, Breastfeeding (ORP-40) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Patients monitoring during treatment with Teriflunomide (ORP-41) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis The Role of Advanced MRI Techniques and Artificial Intelligence-based Methods In Diagnosis of Multiple Sclerosis (ORP-42) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Update on inflammation, neurodegeneration and immunoregulation in MS (ORP-44) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Treatment escalation vs early high efficacy treatment in multiple sclerosis (cons and pros) (ORP-45) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Nutritional recommendations in multiple sclerosis patients: a narrative review (ORP-46) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Paroxysmal Events in Multiple Sclerosis (MS); Pseudoathetosis as a Presenting Symptom of MS (ORP-48) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Patient Monitoring during Treatment with Ocrelizumab and Rituximab (ORP-49) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Current Updates on the Use of Probiotics as a New Treatment Option for Multiple Sclerosis (ORP-50) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Management of seizure in patients with multiple sclerosis (ORP-51) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis The role of stereotactic biopsy in atypical brain lesions (ORP-52) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Relationship between severity of symptoms of sleep disorders and information processing speed in people with multiple sclerosis (ORP-53) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis System biology review of multiple sclerosis and discovery of drug targets (ORP-54) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Spinal cord MRI in multiple sclerosis; diagnostic, prognostic, and clinical value (ORP-55) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis A middle-aged woman with history of Multiple sclerosis presented with sub-acute encephalopathy (ORP-58) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Reduction in Circulating Vitamin D Binding Protein in Patients with Multiple sclerosis (ORP-59) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Multiple Sclerosis (MS) and Legal Medical Doctrines (ORP-60) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis MS and Environmental Factors (ORP-61) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Care ethics and empathic Practices in dealing with MS Patients (ORP-62) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis The effects of crocin on inflammatory biomarkers and mental health in patients with multiple sclerosis: a randomized, double-blinded clinical trial (ORP-63) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis A Mechanistic Insight into Sources of Error of Visual Working Memory in Multiple Sclerosis (PP-01) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Alopecia universalis in a patient under treatment of Ocrelizumab after switching from Rituximab (PP-06) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Artificial intelligence in multiple sclerosis imaging: advancements, benefits, and challenges (PP-07) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Benign Paroxysmal Positioning Vertigo in Multiple Sclerosis (PP-09) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Cardiovascular autonomic dysfunction in MS (PP-10) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Comparing the Impact of Bariatric Surgery and Diet Therapy on MS Disease-Related Symptoms: A Systematic Review Study (PP-12) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Demyelinating etiology as a possible cause of Parry–Romberg Syndrome (PP-14) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Diagnosis of multiple sclerosis and Fahr's Disease in a young woman: A case report (PP-15) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Early Clinical Response and Complications of Therapeutic Plasma Exchange in Central Nervous System Demyelinating Diseases (PP-16) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis The Effect of Multiple Sclerosis on Peripheral Audio-Vestibular System (PP-17) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Long-term and Short-term Episodic Memory Dysfunction in Female MS Patients (PP-18) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Headache first manifestation of Multiple Sclerosis (PP-19) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Investigating the relationship between stress, anxiety and depression with the quality (PP-20) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Is There a Need to Differentiate Atypical Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorders (NMOSD)? The Pros and Cons: A Systematic Review (PP-21) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Lingual dystonia as the first manifestation of multiple sclerosis (PP-22) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis MS and exercise (PP-23) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Multidisciplinary rehabilitative management (PP-24) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review (PP-25) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Neurosarcoidosis in an adult man with a family history of MS: A Case report (PP-26) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Patterns of Attention Deficit in Relapsing and Progressive Phenotypes of Multiple Sclerosis (PP-27) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Personality traits of patients with multiple sclerosis and their correlation with anxiety and depression levels: A cross-sectional case-control study (PP-28) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Comparison of COVID-19 infection, Acute Relapse, and Adverse Effects Following COVID-19 Vaccination Between Patients with Multiple Sclerosis and Other Neurological Disorders (PP-29) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis Pharmacogenomics of Multiple Sclerosis: Sieving treatment biomarkers from blood gene-expression profiles (PP-30) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple sclerosis functional composite How to estimate the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis? (ORP-43) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Multiple Sclerosis (MS) MS Prodrome; Is it a fact? (ORP-02) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Music Mind and Art (ORP-01) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

N

  • Natalizumab Patient monitoring during treatment with natalizumab (ORP-24) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Natalizumab A Systematic Review and Meta-analysis on Safety and Effectiveness of Extended-interval Dosing of Natalizumab in Patients with Relapsing-remitting Multiple Sclerosis: Is There Any Value in The Cost of Treatment? (PP-08) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Neural Stem Cell Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases [Volume 2, Issue 2, 2023, Pages 55-68]
  • Neurodegeneration Update on inflammation, neurodegeneration and immunoregulation in MS (ORP-44) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Neurodegenerative Diseases Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases [Volume 2, Issue 2, 2023, Pages 55-68]
  • Neurological disorder The Interplay Between the Gut Microbiome and Neurological Disorders: Exploring the Gut-Brain Axis [Volume 2, Issue 1, 2023, Pages 25-29]
  • Neuromyelitis Optica Spectrum Disorder Acute Relapses of Neuromyelitis Optica Spectrum Disorder After COVID-19 Vaccination Shot, Among Iranian Patients (PP-05) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Neuromyelitis optica spectrum disorders Neuromyelitis Optica Spectrum Disorders (NMOSD); Diagnostic criteria (ORP-56) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Neuromyelitis optica spectrum disorders Is There a Need to Differentiate Atypical Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorders (NMOSD)? The Pros and Cons: A Systematic Review (PP-21) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Neurosarcoidosis Neurosarcoidosis in an adult man with a family history of MS: A Case report (PP-26) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • NMOSD Neuromyelitis Optica Spectrum Disorders (NMOSD); Diagnostic criteria (ORP-56) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • NMOSD Acute Brainstem syndrome with NMOSD and related to systemic lupus erythematosus, A Rare Case Report (PP-02) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

O

  • Obstructive Sleep Apnea Sleep Disturbances and Disease Characteristics of Patients with Multiple Sclerosis in Iran: A Cross-sectional Study (ORP-32) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Obstructive Sleep Apnea Relationship between severity of symptoms of sleep disorders and information processing speed in people with multiple sclerosis (ORP-53) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Ocrelizumab Patient Monitoring during Treatment with Ocrelizumab and Rituximab (ORP-49) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Ocrelizumab Alopecia universalis in a patient under treatment of Ocrelizumab after switching from Rituximab (PP-06) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Optical coherence tomography Optical Coherence Tomography (OCT) Measurements and Disability in Multiple Sclerosis (MS): Protocol of Systematic Review [Volume 2, Issue 1, 2023, Pages 44-46]
  • Optic neuritis Optic neuritis and autoimmune optic neuropathies (ORP-35) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Optic neuritis Optic neuritis updates (ORP-57) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Optic neuropathies Ophthalmology in multiple sclerosis (ORP-47) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Osteonecrosis Femoral head AVN concept and treatments (ORP-16) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Other neurological disease Comparison of COVID-19 infection, Acute Relapse, and Adverse Effects Following COVID-19 Vaccination Between Patients with Multiple Sclerosis and Other Neurological Disorders (PP-29) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Overlap syndrome Is There a Need to Differentiate Atypical Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorders (NMOSD)? The Pros and Cons: A Systematic Review (PP-21) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

P

  • Parkinson's disease Autonomic dysfunction and fatigue in Parkinson’s disease: a report from Kenya [Volume 2, Issue 1, 2023, Pages 47-50]
  • Parkinson's disease Restless Leg Syndrome and Impulse-Control Disorders in Parkinson’s Disease: Observational study [Volume 2, Issue 1, 2023, Pages 51-54]
  • Parry–Romberg Syndrome Demyelinating etiology as a possible cause of Parry–Romberg Syndrome (PP-14) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Pharmacogenomics Pharmacogenomics of Multiple Sclerosis: Sieving treatment biomarkers from blood gene-expression profiles (PP-30) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Phenotype Patterns of Attention Deficit in Relapsing and Progressive Phenotypes of Multiple Sclerosis (PP-27) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Physiotherapy New Technological Approach to Physical Therapy in Patients with Multiple Sclerosis (ORP-25) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • PML Patient monitoring during treatment with natalizumab (ORP-24) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Post Stroke Depression Cognitive Functions of Patients with Post Stroke Depression: Comparative Study on Executive Functions, Processing Speed, and Episodic Memory [Volume 2, Issue 2, 2023, Pages 87-96]
  • Practice New Technological Approach to Physical Therapy in Patients with Multiple Sclerosis (ORP-25) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Pregnancy Multiple sclerosis, Pregnancy, Breastfeeding (ORP-40) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Prevalence Restless Leg Syndrome and Impulse-Control Disorders in Parkinson’s Disease: Observational study [Volume 2, Issue 1, 2023, Pages 51-54]
  • Prevention MS Prodrome; Is it a fact? (ORP-02) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Prion disease Exploring the Potential of Biomarkers for Early Diagnosis and Management of Sporadic Creutzfeldt - Jakob disease; A Review [Volume 2, Issue 2, 2023, Pages 78-86]
  • Propranolol Comparison of the Effect of Botulinum Toxin Injection Under Ultrasound Guidance and Oral Propranolol in the Treatment of Moderate to Severe Essential Hand Tremor [Volume 2, Issue 2, 2023, Pages 69-77]
  • Pseudoathetosis Paroxysmal Events in Multiple Sclerosis (MS); Pseudoathetosis as a Presenting Symptom of MS (ORP-48) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Psoriasis Demyelinating Disease Following Anti-TNFa Treatment (Adalimumab) in Patients with psoriasis: A Case Report (PP-13) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Psychophysics Patterns of Attention Deficit in Relapsing and Progressive Phenotypes of Multiple Sclerosis (PP-27) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

Q

  • QEEG Quantitative Electroencephalography Findings in Treatment-resistant and Responsive Patients with Idiopathic Generalized Tonic-Clonic Epilepsy [Volume 2, Issue 1, 2023, Pages 6-12]
  • Quality of Life Effect of eight weeks of respiratory muscle training on respiratory capacity, functional capacity, and quality of life on subjects with mild to moderate relapsing-remitting multiple sclerosis (ORP-33) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Quality of Life Investigating the relationship between stress, anxiety and depression with the quality (PP-20) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Quantitative Electroencephalography Quantitative Electroencephalography Findings in Treatment-resistant and Responsive Patients with Idiopathic Generalized Tonic-Clonic Epilepsy [Volume 2, Issue 1, 2023, Pages 6-12]

R

  • Radiologically isolated syndrome Demyelinating etiology as a possible cause of Parry–Romberg Syndrome (PP-14) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Recommendation Nutritional recommendations in multiple sclerosis patients: a narrative review (ORP-46) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Regenerative medicine Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases [Volume 2, Issue 2, 2023, Pages 55-68]
  • Registry Epidemiological view of national MS registry in Iran (NMSRI) (ORP-27) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Rehabilitation New Technological Approach to Physical Therapy in Patients with Multiple Sclerosis (ORP-25) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Relapse Definition and treatment of the multiple sclerosis relapse (ORP-10) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Relapse Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review (PP-25) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Relapsing Remitting Multiple Sclerosis Headache first manifestation of Multiple Sclerosis (PP-19) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Repositioning Maneuvers Benign Paroxysmal Positioning Vertigo in Multiple Sclerosis (PP-09) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Resource model A Mechanistic Insight into Sources of Error of Visual Working Memory in Multiple Sclerosis (PP-01) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Rest leg syndrome Sleep Disturbances and Disease Characteristics of Patients with Multiple Sclerosis in Iran: A Cross-sectional Study (ORP-32) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Restless Leg Syndrome Restless Leg Syndrome and Impulse-Control Disorders in Parkinson’s Disease: Observational study [Volume 2, Issue 1, 2023, Pages 51-54]
  • Restless Leg Syndrome Relationship between severity of symptoms of sleep disorders and information processing speed in people with multiple sclerosis (ORP-53) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Rituximab Clinical Outcome and Volumetric MRI Assessment of Brain and Cervical Spinal Cord Area in Secondary Progressive Multiple Sclerosis Patients Treated with Rituximab: one-year follow-up (ORP-08) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Rituximab Patient Monitoring during Treatment with Ocrelizumab and Rituximab (ORP-49) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • RRMS Headache first manifestation of Multiple Sclerosis (PP-19) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

S

  • Saffron The effects of crocin on inflammatory biomarkers and mental health in patients with multiple sclerosis: a randomized, double-blinded clinical trial (ORP-63) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • SARS-CoV-2 Acute disseminated encephalomyelitis following vaccination against SARS-cov-2: a case report (PP-04) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • SARS-CoV-2 Comparison of COVID-19 infection, Acute Relapse, and Adverse Effects Following COVID-19 Vaccination Between Patients with Multiple Sclerosis and Other Neurological Disorders (PP-29) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Schilder's disease MS Variants (ORP-38) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Secondary Progressive Multiple Sclerosis Clinical Outcome and Volumetric MRI Assessment of Brain and Cervical Spinal Cord Area in Secondary Progressive Multiple Sclerosis Patients Treated with Rituximab: one-year follow-up (ORP-08) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Seizure Defining seizure type and frequency, and analyzing MRI and EEG findings in MS populations of Khorasan. A cross-sectional study (ORP-21) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Seizure EEG Patterns in MS-related epilepsy A literature Review (ORP-26) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Seizure Management of seizure in patients with multiple sclerosis (ORP-51) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Solitary Sclerosis MS Variants (ORP-38) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Stress Investigating the relationship between stress, anxiety and depression with the quality (PP-20) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Swap error A Mechanistic Insight into Sources of Error of Visual Working Memory in Multiple Sclerosis (PP-01) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • System biology System biology review of multiple sclerosis and discovery of drug targets (ORP-54) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

T

  • Targeted therapies Personalized Treatment for Multiple Sclerosis: The Role of Precision Medicine [Volume 2, Issue 1, 2023, Pages 30-34]
  • TDP-43 Current understanding of the association between Amyotrophic lateral sclerosis and frontotemporal dementia: Letter to Editor [Volume 2, Issue 1, 2023, Pages 42-43]
  • Technological-based approach New Technological Approach to Physical Therapy in Patients with Multiple Sclerosis (ORP-25) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Tinitus Headache first manifestation of Multiple Sclerosis (PP-19) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Tonic-clonic seizure Quantitative Electroencephalography Findings in Treatment-resistant and Responsive Patients with Idiopathic Generalized Tonic-Clonic Epilepsy [Volume 2, Issue 1, 2023, Pages 6-12]
  • True vertigo Headache first manifestation of Multiple Sclerosis (PP-19) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

U

  • Ulcerative colitis Guillain-Barré syndrome in remission of Ulcerative colitis: a case report [Volume 2, Issue 1, 2023, Pages 13-15]
  • Ultrasound Comparison of the Effect of Botulinum Toxin Injection Under Ultrasound Guidance and Oral Propranolol in the Treatment of Moderate to Severe Essential Hand Tremor [Volume 2, Issue 2, 2023, Pages 69-77]
  • Uveitis Ophthalmology in multiple sclerosis (ORP-47) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

V

  • Vaccination Everything we need to know about vaccination in MS (ORP-12) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Vaccine COVID-19 vaccine-hesitancy is associated with lower cortical volume in elderly individuals [Volume 2, Issue 1, 2023, Pages 35-41]
  • Vaccine Comparison of COVID-19 infection, Acute Relapse, and Adverse Effects Following COVID-19 Vaccination Between Patients with Multiple Sclerosis and Other Neurological Disorders (PP-29) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Vertigo The Effect of Multiple Sclerosis on Peripheral Audio-Vestibular System (PP-17) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Vestibular Function The Effect of Multiple Sclerosis on Peripheral Audio-Vestibular System (PP-17) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Vitamin D Reduction in Circulating Vitamin D Binding Protein in Patients with Multiple sclerosis (ORP-59) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]
  • Vitamin D binding protein Reduction in Circulating Vitamin D Binding Protein in Patients with Multiple sclerosis (ORP-59) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]

W

  • Women Women and Multiple Sclerosis (ORP-07) [Volume 2, Supplementary 1 (20th Iranian Multiple Sclerosis Congress), 2023]